Denosumab vs Risedronate Improves Bone Mineral Density in Glucocorticoid-Induced Osteoporosis and RA
>
>
Denosumab vs Risedronate Improves Bone Mineral Density in Glucocorticoid-Induced Osteoporosis and RA

Denosumab vs Risedronate Improves Bone Mineral Density in Glucocorticoid-Induced Osteoporosis and RA

Compared with risedronate, denosumab was found to improve bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis and rheumatoid arthritis (RA); however, the safety profile was similar between both treatment.

A significant mean difference (95% CI) in percent change from baseline in BMD was observed between the 2 groups at lumbar spine, total hip, and femoral neck at month 12 (1.8%, 1.9%, and 1.5%, respectively) and month 24.

Read More: Adachi J, Chines A, Huang S, Saag K, Lems W, Geusens P. Safety and efficacy of denosumab vs risedronate in patients with glucocorticoid-induced osteoporosis and rheumatoid arthritis. Presented at: ACR Convergence 2021; November 3-10, 2021. Abstract 0445

Share on

There are no comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Start typing and press Enter to search

Shopping Cart